Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2024-09-11 Legal Proceedings Report
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
소송등의판결ㆍ결정
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory disclosure regarding a legal proceeding ('소송등의판결ㆍ결정'), specifically the withdrawal of a shareholder request for inspection of the shareholder register. It details the case name, court, and the outcome (withdrawal of the application). This falls under the category of legal proceedings and regulatory disclosures.
2024-09-11 Korean
풍문또는보도에대한해명(미확정)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding a 'Clarification of Rumors or Reports' (풍문 또는 보도에 대한 해명). It addresses a specific media report about potential financing and states that no decision has been made yet. Since this is a standard regulatory disclosure regarding market rumors and does not fit into specific categories like M&A or Capital Updates (as it is explicitly 'undecided'), it falls under the general regulatory filing category.
2024-09-05 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from Cha Biotech regarding the 'Decision to Issue Convertible Bonds' (전환사채권 발행결정). It details the specific terms of the bond issuance, including interest rates, conversion prices, put/call options, and the use of proceeds. This is a formal regulatory filing required by the Korea Exchange (KRX) for material corporate events, specifically related to capital structure changes and financing. It fits the 'Share Issue/Capital Change' (SHA) category as it pertains to the issuance of convertible securities that impact the company's capital structure.
2024-08-22 Korean
[기재정정]주요사항보고서(신주인수권부사채권발행결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Korean financial authorities (Financial Services Commission/Korea Exchange). It specifically details the 'Decision to Issue Bonds with Warrants' (신주인수권부사채 발행결정) and includes a correction (정정신고) regarding the use of proceeds and counterparty information. This type of regulatory filing for capital structure changes, such as bond issuance, falls under the 'Regulatory Filings' category as it is a formal disclosure of corporate financial activity.
2024-08-22 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 100% confidence The document is a regulatory filing from the Korean DART system (indicated by the format and content) regarding the 'Decision to Acquire Shares and Securities of Another Corporation' (타법인주식및출자증권취득결정). This is a standard corporate disclosure for M&A or investment activity where a company acquires shares in another entity. Since it details the acquisition of shares in a subsidiary (Cha Healthcare) to fulfill a contractual obligation, it falls under the category of M&A activity/corporate investment updates.
2024-08-22 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '차바이오텍' (Chabiotech Co., Ltd.) covering the period from January 1, 2024, to June 30, 2024. It contains detailed corporate information, management discussion, capital structure, and financial data. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year (like a half-year report) is classified as an Interim / Quarterly Report (IR). H1 2024
2024-08-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.